RPRX as reported
Royalty Pharma plc reported $2.54B of revenue over the trailing twelve months, +10% on the year before. 9 reported series are charted on this page, each one as filed.
$2.54B
Revenue, trailing twelve months · to Q2 2026 · +10% against the twelve months before
- Net Income
- $815M
Net Income · −20% year on year · trailing twelve months to Q2 2026
- Op Margin
- 60%
Op Margin · trailing twelve months to Q2 2026
- EPS
- $1.88
EPS · −18% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $2.54B | +10% | Q2 2026 |
| Net Income | $815M | −20% | Q2 2026 |
| EPS | $1.88 | −18% | Q2 2026 |
| Op Margin | 60% | n/a | Q2 2026 |
| Net Margin | 33% | n/a | Q2 2026 |
| ROE | 8.2% | n/a | Q2 2026 |
| ROA | 4.1% | n/a | Q2 2026 |
| ROIC | 6.8% | n/a | Q2 2026 |
| P/E | 32.9 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Royalty Pharma plc (RPRX) - Revenue & ProfitRevenue & ProfitRoyalty Pharma plc (RPRX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com